Lates News

According to the AI briefing, Dongwu Securities issued a research report on January 12th, giving Xianle Health (300791.SZ) a "buy" rating. The rating reasons mainly include: 1) Xianle Health is a leading company in the health product CDMO industry; 2) The health product industry is developing in a decentralized manner, benefiting the CDMO segment; 3) With a global perspective, steady growth in Europe, and improvements in the Americas; 4) The importance of new retail customers is increasing. (Daily Economic News)